-- The neurotechnology company Pulsetto has received a 2025 Global Recognition Award for converting medical-grade vagus nerve stimulation into a consumer wellness device accessible to all. The company addresses the rapidly growing mental health technology market while capitalizing on escalating global stress levels and increasing demand for non-pharmaceutical wellness solutions that provide measurable results. The recognition acknowledges Pulsetto's ability to bridge the gap between clinical-grade interventions and everyday consumer products, which demonstrates how advanced medical technology can be redesigned for widespread adoption.
Photo Courtesy of Pulsetto
CEO and co-founder Povilas Sabaliauskas experienced the loss of his father to unexplained causes, while co-founder Vitalijus Majorovas witnessed his wife's struggle with cluster headaches that resisted conventional treatment and pharmaceutical options. These personal experiences motivated the development of Pulsetto's bilateral vagus nerve stimulation device, which now serves more than 130,000 active users across more than 70 countries. and continues to expand its global footprint through strategic market positioning. The founders transformed their personal healthcare challenges into a business opportunity that addresses similar struggles faced by millions of people worldwide who seek alternatives to traditional pharmaceutical interventions. Their approach combines a personal understanding of patient needs with rigorous product development, enabling the company to create a solution that resonates with consumers seeking evidence-based wellness technology.
Revenue Growth and Market Expansion
The company achieved notable financial growth, with revenue reaching €10.9 million in the first half of 2025, surpassing the entire 2024 performance of €10 million within six months and demonstrated accelerating market acceptance. Second-quarter 2025 revenue reached €6.65 million, marking a 55.61 percent growth over the first quarter. This momentum reflects strong consumer demand for non-invasive neurotechnology solutions that deliver clinically validated benefits. The financial trajectory positions Pulsetto as a leading player in the consumer neurotechnology sector, where the company has successfully converted clinical innovation into a scalable business model that generates consistent revenue growth.
The company has launched retail operations in London (Selfridges Smartech, Boots) and New York (TM:RW in Times Square, Walmart), as part of its continued expansion, which demonstrates the global demand for accessible stress management technology that bridges medical efficacy with consumer convenience. This retail strategy complements the company's existing distribution channels while providing customers with hands-on product experiences that can accelerate adoption rates and build brand recognition in key metropolitan markets. The expansion reflects Pulsetto's confidence in sustained market demand, and the physical retail presence will enable the company to strengthen its position in competitive urban markets where health-conscious consumers actively seek innovative wellness solutions.
Clinical Validation and Product Performance
Pulsetto FIT device offers a hands-free, bilateral wearable solution that delivers four-minute sessions designed to activate the body's natural relaxation response through targeted nerve stimulation. Users can choose from five preset modes targeting stress, anxiety, burnout, sleep, and pain relief. The device includes nine intensity levels, allowing for personalization based on individual comfort preferences and therapeutic needs. The product design prioritizes user experience by eliminating the need for handheld operation, allowing people to seamlessly incorporate the technology into their daily routines without disrupting their activities or requiring dedicated intervention time.
Clinical trials demonstrated measurable health improvements across multiple assessments, where depression symptoms decreased by 56 percent and anxiety was reduced by 45 percent among study participants who used the device according to recommended protocols. Sleep quality improved by 41 percent among users, and the company reports that 86 percent of users experienced reduced anxiety after two weeks of regular use, which validates the device's effectiveness across diverse health metrics, such as improved HRV, reduced cortical as lower heart rate. After 15 sessions with the device, 64.5 percent of users experienced sustained anxiety and stress reduction that extended beyond the immediate usage period, and these results confirm the device's ability to produce lasting physiological changes rather than temporary symptomatic relief.
The company's approach addresses documented challenges in mental health management, since antidepressant use in Western countries increased 66 percent over six years, while 40 percent of people turn to alcohol and 38 percent to smoking for stress relief despite the known health risks associated with these coping mechanisms. Pulsetto offers a non-pharmaceutical intervention that integrates firmware, app control, and hardware design into a wearable form factor. This combination allows users to incorporate the technology into their daily routines without requiring medical supervision or a prescription. The combination of clinical evidence, user adoption rates, and revenue growth validates strong market demand for accessible stress management technology that provides measurable physiological benefits without the side effects commonly associated with pharmaceutical interventions.
Final Words
Alex Sterling, spokesperson for Global Recognition Awards, remarked, "Pulsetto has demonstrated how consumer product design and scientific integrity can coexist, while the company's ability to scale a neurotechnology solution and maintain rigorous clinical validation sets a new standard for the wellness technology sector." The work of Sabaliauskas and Majorovas positions vagus nerve stimulation as a practical intervention for stress-related health challenges affecting millions globally, and their success illustrates how founders can convert personal tragedy into innovation that serves a broader population seeking alternatives to conventional treatment approaches. Pulsetto's trajectory demonstrates how personal healthcare experiences, combined with strong business execution, can create a meaningful market impact when coupled with user-centered design principles and a commitment to evidence-based product development.
The recognition through this award acknowledges the technical merit of its bilateral stimulation approach and the company's success in making previously inaccessible medical technology available to everyday consumers who seek evidence-based alternatives to pharmaceutical stress management. After 15 sessions with the device, 64.5 percent of users experienced a reduction in anxiety and stress, providing sustained relief in everyday life, which validated the device's effectiveness beyond the initial usage period. The company has converted a clinical intervention into a product that over 60,000 people use regularly, which demonstrates that complex nervous system regulation can be made accessible through thoughtful design and strategic market positioning. This achievement represents a significant shift in how neurotechnology reaches consumers while setting new standards for how wellness companies can successfully translate medical-grade interventions into products that meet both clinical standards and consumer expectations for convenience and usability.
About Global Recognition Awards
The Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their respective industries.
Contact Info:
Name: Alexander Sterling
Email: Send Email
Organization: Global Recognition Awards
Website: https://globalrecognitionawards.org
Release ID: 89176598
Google
RSS